Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  Can Artificial intelligence and/or Optical Coherence Tomography be used to prevent blindness and maintain well-being in older people with Macular Degeneration?


   MRC DiMeN Doctoral Training Partnership

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Prof Richard Gale, Prof Tariq Aslam  No more applications being accepted  Competition Funded PhD Project (Students Worldwide)

About the Project

This is an exceptional opportunity to join a very strong team of clinical academic, scientific and industry partners with a track record of delivering the highest quality research. A successful candidate will be able to shape this applied project that will have far reaching impact. It is suitable for applicants from a number of backgrounds or for those wanting to develop in a number of different areas, for example Health Sciences, Computer Science or Psychology. Aspects of the project can be tailored to a successful candidate.

Dry Age-related macular degeneration (AMD) is a condition affecting the central vision of 600,000 people over the age of 50 in the UK with significant impact on well-being. Wet AMD (wAMD) is a rapidly progressing subgroup that develops from dry AMD, affects 40,000 new people in the UK every year and requires regular eye injections. The average age at presentation of wAMD is 80 years with the second eye becoming involved in a quarter or affected people within 3 years. Early detection with a commonly available optical coherence tomography (OCT) imaging based approach has the potential to identify those at risk at a stage where visual loss can minimised with treatment. The NHS is challenged with insufficient capacity in the traditional hospital setting to offer monitoring of those at high risk of disease.

The purpose of this project is  

  1. to evaluate the ability to identify individuals at high risk of developing the wAMD, 
  2. to evaluate participant acceptability to undertake Optical Coherence Tomography monitoring in a non-hospital setting,
  3. to assess participants well-being, and
  4. to evaluate the role of artificial intelligence in the process. 

Participants with high risk dry AMD will be recruited from community optometrists, Diabetic Eye disease screening services and Hospital eye services as a part of routine care, and would be randomised to this observation study to either continue with standard care (home paper based monitoring and routine optometry visits) or to enter an OCT based monitoring programme. Key end points are adherence, acceptability and wellbeing at 12 months. Additional end points are numbers of participants developing wet AMD and their visual acuity at the point of conversion. An important end point is to assess if an image detection artificial intelligence algorithm would accurately identify early development.

There is currently no screening or monitoring program for such individuals’ risk of this disease in the UK. This work will form part of a growing body of evidence to call for such a program and it potentially very impactful across the UK and beyond.

A successful candidate will not only benefit from supervision from leading International experts in the field and but will also join a community of York Biomedical Research Institute Doctoral students. The research environment is not only supportive and provides training in basic methodology but is also fun!

We look forward to welcoming you.

Twitter: @YorkEyeResearch

https://www.researchgate.net/profile/Richard-Gale-3

https://www.research.manchester.ac.uk/portal/tariq.aslam.html

https://www.cs.york.ac.uk/people/?group=Academic%20and%20Teaching%20Staff&username=pirs

https://www.york.ac.uk/psychology/staff/academicstaff/arm501/#profile-content

We are proud to be partnered with one of the largest investors in Eye health care globally.

https://www.roche.com/solutions/focus-areas/ophthalmology

Benefits of being in the DiMeN DTP:

This project is part of the Discovery Medicine North Doctoral Training Partnership (DiMeN DTP), a diverse community of PhD students across the North of England researching the major health problems facing the world today. Our partner institutions (Universities of Leeds, Liverpool, Newcastle, York and Sheffield) are internationally recognised as centres of research excellence and can offer you access to state-of the-art facilities to deliver high impact research.

We are very proud of our student-centred ethos and committed to supporting you throughout your PhD. As part of the DTP, we offer bespoke training in key skills sought after in early career researchers, as well as opportunities to broaden your career horizons in a range of non-academic sectors.

Being funded by the MRC means you can access additional funding for research placements, international training opportunities or internships in science policy, science communication and beyond. See how our current DiMeN students have benefited from this funding here: https://www.dimen.org.uk/blog 

Further information on the programme and how to apply can be found on our website:

https://www.dimen.org.uk/how-to-apply 


Biological Sciences (4) Computer Science (8) Engineering (12) Mathematics (25) Medicine (26)

Funding Notes

iCASE Award: Industrial partnership project
Fully funded by the MRC for 4yrs, including a minimum of 3 months working with an industry partner.

Funding will cover tuition fees and an enhanced stipend (around £20,168). We also aim to support the most outstanding applicants from outside the UK and are able to offer a limited number of full studentships to international applicants. Please read additional guidance here: https://www.dimen.org.uk/eligibility-criteria
Studentships commence: 1st October 2023
Good luck!

References

The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. doi.org/10.1111/aos.15201. July 2022. Richard P. Gale, Robert P. Finger, Bora Eldem, Tariq Aslam, Jane Barratt, Vincent Daien, Laurent Kodjikian, Anat Loewenstein, Mali Okada, Tien Yin Wong, Michelle Sylvanowicz, Francisco J. Rodríguez
Predicting myocardial infarction through retinal scans and minimal personal information Nature Machine INtellgence: doi.org/10.1038/s42256-021-00427-7. Andres Diaz-Pinto, Nishant Ravikumar, Rahman Attar, Avan Suinesiaputra, Yitian Zhao, Eylem Levelt, Erica Dall’Armellina, Marco Lorenzi, Qingyu Chen, Tiarnan D. L. Keenan, Elvira Agrón, Emily Y. Chew, Zhiyong Lu6, Chris P. Gale, Richard P. Gale, Sven Plein, Alejandro F. Frangi.

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study. Ophthalmology. 2021 Dec; 128(12): 1736–1747. doi: 10.1016/j.ophtha.2021.07.025. Sobha Sivaprasad, Katie Banister, Augusto Azuro-Blanco, Beatriz Goulao, Jonathan A. Cook, Ruth Hogg, Graham Scotland, Heinrich Heimann, Andrew Lotery, Faruque Ghanchi, Richard Gale, Geeta Menon, Louise Downey, Nicola Hopkins, Peter Scanlon, Ben Burton, Craig Ramsay, Usha Chakravarthy
Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond) 2019 Mar; 33(Suppl 1): 1–21. Published online 2019 Mar 29. doi: 10.1038/s41433-018-0300-3 Richard P. Gale, Sajjad Mahmood, Helen Devonport, Praveen J. Patel, Adam H. Ross, Gavin Walters, Louise Downey, Samer El-Sherbiny, Mary Freeman, Simon Berry, Nitin Jain

Cortical Atrophy Predicts Visual Performance in Long-Term Central Retinal Disease; GCL, pRNFL and Cortical Thickness Are Key Biomarkers Invest Ophthalmol Vis Sci. 2022 May; 63(5): 35. Published online 2022 May 27. doi: 10.1167/iovs.63.5.35. Rachel L. W. Hanson, Heidi A. Baseler, Archana Airody, Antony B. Morland, Richard P. Gale
Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review Ophthalmol Ther. 2020 Dec; 9(4): 725–737. Published online 2020 Aug 8. doi: 10.1007/s40123-020-00288-0 Claire R. Gill, Catherine E. Hewitt, Tracy Lightfoot, Richard P. Gale

Where will I study?